Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10893730 | 0.91 | POLB (0.71) | POLBALDH1A1 | |
| SCHEMBL28742538 | 0.91 | POLB (0.86) | POLBKMT2AMEN1 | |
| SCHEMBL22291866 | 0.88 | POLB (0.81) | POLBALDH1A1 | |
| SCHEMBL13903018 | 0.87 | POLB (0.62) | POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL20325057 | 0.87 | POLB (0.74) | POLBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL10963023 | 0.86 | POLB (0.78) | POLBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL3199349 | 0.86 | POLB (0.78) | POLBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL15304610 | 0.86 | POLB (0.68) | POLBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL14281446 | 0.85 | POLB (0.60) | POLBKMT2AMEN1ATMALDH1A1 | |
| SCHEMBL6650418 | 0.85 | CNR1 (0.77) | POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | CANO IVAN COLLADO | 2009-03-05 | — | — | US | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1335908-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | LILLY CO ELI (US) | 2008-02-13 | — | — | EP | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304062-B2 | Peroxisome proliferator activated receptor alpha agonists | ELI LILLY AND COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | disclosed |
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | CANO IVAN COLLADO (ES) | 2004-05-27 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| EP-1335908-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| EP-1274411-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | Axon Biochemicals B.V. (NL) | 2003-01-15 | — | — | EP | disclosed |
| WO-2002038553-A2 | TRIAZOLE DERIVATIVES AND THEIR USE AS PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001078713-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | AXON BIOCHEMICALS B.V. (NL) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | POLB 887/4885KMT2A 1849/4885MEN1 3851/4885 |
| US-20040102500-A1 | Peroxisome proliferator activated receptor alpha agonists | PPARG, PPARA, PPARD | POLB 2075/4885KMT2A 3230/4885MEN1 4880/4885 |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | POLB 897/4885KMT2A 1819/4885MEN1 3932/4885 |
| US-20090062358-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS | PPARG, PPARA, PPARD | POLB 2020/4885KMT2A 3695/4885MEN1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.